ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,469.30
      0.00%
      US Tech 100
      19,154.80
      -0.11%
      Dow Jones
      39,112.16
      0.00%
      Brent Oil
      84.35
      0.20%
      Bitcoin
      61,428.87
      -0.62%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Neumora Therapeutics Inc (NMRA)

      7. Neumora Therapeutics Inc (NMRA) News

      NMRA

      Neumora Therapeutics (NMRA)

      Neumora Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:NMRA
      DateTimeSourceHeadlineSymbolCompany
      06/20/20247:00AMGlobeNewswire Inc.Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease AgitationNASDAQ:NMRANeumora Therapeutics Inc
      06/14/20244:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
      06/14/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
      05/14/20247:00AMGlobeNewswire Inc.Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar DepressionNASDAQ:NMRANeumora Therapeutics Inc
      05/07/20244:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NMRANeumora Therapeutics Inc
      05/07/20247:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
      05/07/20247:00AMGlobeNewswire Inc.Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:NMRANeumora Therapeutics Inc
      05/06/20247:00AMGlobeNewswire Inc.Neumora Therapeutics to Participate in Upcoming Conferences in MayNASDAQ:NMRANeumora Therapeutics Inc
      04/15/20246:30AMGlobeNewswire Inc.Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 StudyNASDAQ:NMRANeumora Therapeutics Inc
      03/13/20247:00AMGlobeNewswire Inc.Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS DaysNASDAQ:NMRANeumora Therapeutics Inc
      03/07/20244:34PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NMRANeumora Therapeutics Inc
      03/07/20247:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
      03/07/20247:00AMGlobeNewswire Inc.Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:NMRANeumora Therapeutics Inc
      02/16/20244:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
      02/16/20244:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
      02/16/20244:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
      02/16/20244:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
      01/22/20247:00AMGlobeNewswire Inc.Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial OfficerNASDAQ:NMRANeumora Therapeutics Inc
      01/08/20248:32AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
      01/02/20247:00AMGlobeNewswire Inc.Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NMRANeumora Therapeutics Inc
      12/15/20235:06PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NMRANeumora Therapeutics Inc
      12/12/20237:00AMGlobeNewswire Inc.Neumora Therapeutics Appoints Jason Duncan as Chief Legal OfficerNASDAQ:NMRANeumora Therapeutics Inc
      11/28/20234:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
      11/27/20237:00AMGlobeNewswire Inc.Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical StudyNASDAQ:NMRANeumora Therapeutics Inc
      11/01/20234:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NMRANeumora Therapeutics Inc
      11/01/20234:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
      11/01/20237:00AMGlobeNewswire Inc.Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NMRANeumora Therapeutics Inc
      10/30/20237:00AMGlobeNewswire Inc.Neumora Therapeutics to Participate in Upcoming Conferences in NovemberNASDAQ:NMRANeumora Therapeutics Inc
      10/10/20237:00AMGlobeNewswire Inc.Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and DevelopmentNASDAQ:NMRANeumora Therapeutics Inc
      09/19/20236:51PMKR Market News인스타카트, 나스닥 데뷔로 주가는 12% 상승NASDAQ:NMRANeumora Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:NMRA